UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity

Thrombosis and haemostasis, 2010-06, Vol.103 (6), p.1116-1127

2010

Volltextzugriff (PDF)

Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab

Thrombosis and haemostasis, 2015-07, Vol.113 (4), p.728-740

2015

Volltextzugriff (PDF)

Interpretation of Point-of-care INR Results in Patients Treated with Dabigatran

The American journal of medicine, 2012-04, Vol.125 (4), p.417-420

2012

Volltextzugriff (PDF)

A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran

Thrombosis and haemostasis, 2015-05, Vol.113 (5), p.943-951

2015

Volltextzugriff (PDF)

Effects of Dabigatran in Mouse Models of Aging and Cerebral Amyloid Angiopathy

Frontiers in neurology, 2019-09, Vol.10, p.966-966

2019

Volltextzugriff (PDF)

Use of dabigatran etexilate to reduce breast cancer progression

Cancer biology & therapy, 2010-11, Vol.10 (10), p.1001-1008

2010

Volltextzugriff (PDF)

A specific antidote for dabigatran: functional and structural characterization

Blood, 2013-05, Vol.121 (18), p.3554-3562

2013

Volltextzugriff (PDF)

Idarucizumab for Dabigatran Reversal — Full Cohort Analysis

The New England journal of medicine, 2017-08, Vol.377 (5), p.431-441

2017

Volltextzugriff (PDF)

Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial

The Lancet (British edition), 2015-08, Vol.386 (9994), p.680-690

2015

Volltextzugriff (PDF)

Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin

Arteriosclerosis, thrombosis, and vascular biology, 2010-10, Vol.30 (10), p.1885-1889

2010

Volltextzugriff (PDF)

Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment

Journal of the American College of Cardiology, 2019-10, Vol.74 (14), p.1760-1768

2019

Volltextzugriff (PDF)

Thrombin promotes diet-induced obesity through fibrin-driven inflammation

The Journal of clinical investigation, 2017-08, Vol.127 (8), p.3152-3166

2017

Volltextzugriff (PDF)

Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model

Critical care (London, England), 2014-01, Vol.18 (1), p.R27-R27

2014

Volltextzugriff (PDF)

Idarucizumab Improves Outcome in Murine Brain Hemorrhage Related to Dabigatran

Annals of neurology, 2015-07, Vol.78 (1), p.137-141

2015

Volltextzugriff (PDF)

Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease

Blood, 2014-03, Vol.123 (11), p.1747-1756

2014

Volltextzugriff (PDF)

Off‐target effects of oral anticoagulants – vascular effects of vitamin K antagonist and non‐vitamin K antagonist oral anticoagulant dabigatran etexilate

Journal of thrombosis and haemostasis, 2021-05, Vol.19 (5), p.1348-1363

2021

Volltextzugriff (PDF)

Idarucizumab, a Specific Dabigatran Reversal Agent, Reduces Blood Loss in a Porcine Model of Trauma With Dabigatran Anticoagulation

Journal of the American College of Cardiology, 2015-09, Vol.66 (13), p.1518-1519

2015

Volltextzugriff (PDF)

Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice

Drug design, development and therapy, 2015-01, Vol.9 (default), p.5203-5211

2015

Volltextzugriff (PDF)

Comments on—Switching from vitamin K antagonist to dabigatran in atrial fibrillation: differences according to dose

European heart journal. Cardiovascular pharmacotherapy, 2021-01, Vol.7 (1), p.74-74

2021

Volltextzugriff (PDF)

Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model

Thrombosis and haemostasis, 2016, Vol.115 (2), p.271-284

2016

Volltextzugriff (PDF)

Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects

The American journal of medicine, 2016-11, Vol.129 (11), p.S64-S72

2016

Volltextzugriff (PDF)

Restarting Dabigatran Etexilate 24 h After Reversal With Idarucizumab and Redosing Idarucizumab in Healthy Volunteers

Journal of the American College of Cardiology, 2016-04, Vol.67 (13), p.1654-1656

2016

Volltextzugriff (PDF)

Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease

Arthritis & rheumatology (Hoboken, N.J.), 2011-05, Vol.63 (5), p.1416-1425

2011

Volltextzugriff (PDF)

Thrombin inhibition and cisplatin block tumor progression in ovarian cancer by alleviating the immunosuppressive microenvironment

Oncotarget, 2016-12, Vol.7 (51), p.85291-85305

2016

Volltextzugriff (PDF)

Idarucizumab, but not procoagulant concentrates, fully restores dabigatran‐altered platelet and fibrin components of hemostasis

Transfusion (Philadelphia, Pa.), 2019-07, Vol.59 (7), p.2436-2445

2019

Volltextzugriff (PDF)

1 – 25 von 116

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(109)
Mit Volltextzugriff
(96)

Publikationsform

Sprache

Englisch
(116)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(64)
Life Sciences & Biomedicine
(62)
Animals
(37)
Dabigatran
(36)
Humans
(33)
Male
(27)
Cardiovascular System & Cardiology
(25)
Blood Coagulation - Drug Effects
(23)
Hematology
(22)
Female
(21)
Anticoagulants
(20)
Peripheral Vascular Disease
(20)
Mice
(15)
Biological And Medical Sciences
(14)
Disease Models, Animal
(14)
Internal Medicine
(13)
Medical Sciences
(13)
Thrombin
(13)
Antibodies, Monoclonal, Humanized - Pharmacology
(12)
Beta-Alanine - Analogs & Derivatives
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity

Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab

Interpretation of Point-of-care INR Results in Patients Treated with Dabigatran

A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran

Effects of Dabigatran in Mouse Models of Aging and Cerebral Amyloid Angiopathy

Use of dabigatran etexilate to reduce breast cancer progression

A specific antidote for dabigatran: functional and structural characterization

Idarucizumab for Dabigatran Reversal — Full Cohort Analysis

Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial

Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin

Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment

Thrombin promotes diet-induced obesity through fibrin-driven inflammation

Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model

Idarucizumab Improves Outcome in Murine Brain Hemorrhage Related to Dabigatran

Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease

Off‐target effects of oral anticoagulants – vascular effects of vitamin K antagonist and non‐vitamin K antagonist oral anticoagulant dabigatran etexilate

Idarucizumab, a Specific Dabigatran Reversal Agent, Reduces Blood Loss in a Porcine Model of Trauma With Dabigatran Anticoagulation

Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice

Comments on—Switching from vitamin K antagonist to dabigatran in atrial fibrillation: differences according to dose

Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model

Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects

Restarting Dabigatran Etexilate 24 h After Reversal With Idarucizumab and Redosing Idarucizumab in Healthy Volunteers

Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease

Thrombin inhibition and cisplatin block tumor progression in ovarian cancer by alleviating the immunosuppressive microenvironment

Idarucizumab, but not procoagulant concentrates, fully restores dabigatran‐altered platelet and fibrin components of hemostasis

Suchergebnisse filtern